Kaspofungin Pliva (Caspofungin)

Caspofungin belongs to the echinocandin class and works by inhibiting the enzyme responsible for synthesizing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. This inhibition weakens the wall, causing osmotic instability and ultimately leading to fungal cell death.

The dose of caspofungin is set by the prescribing clinician based on factors such as the type and severity of the infection, the patient’s body weight, and hepatic or renal function. No fixed regimen is provided here; the prescriber tailors therapy to each individual case.

Safety data for caspofungin in pregnancy and lactation are limited, and the pregnancy category is unknown. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Caspofungin, an echinocandin, targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including some resistant to azoles, but they are administered intravenously.

Kaspofungin Pliva should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the solution. Maintaining the cold chain preserves drug stability and potency.

The medication is given by intravenous infusion. After an initial loading dose, subsequent doses are administered as a slow infusion over approximately one hour, under the supervision of qualified healthcare personnel in a clinical setting.

Serious adverse events include severe hepatic dysfunction, anaphylactic or severe hypersensitivity reactions, acute renal failure, and profound hypotension or cardiovascular collapse. Patients should be monitored closely for signs of these reactions, and therapy should be discontinued if they occur.

Caspofungin is contraindicated in individuals with known hypersensitivity to caspofungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, as well as those receiving concomitant drugs that may cause dangerous interactions without appropriate monitoring.